Kishinevsky, Sarah
Wang, Tai
Rodina, Anna
Chung, Sun Young
Xu, Chao
Philip, John
Taldone, Tony
Joshi, Suhasini
Alpaugh, Mary L.
Bolaender, Alexander
Gutbier, Simon
Sandhu, Davinder
Fattahi, Faranak
Zimmer, Bastian
Shah, Smit K.
Chang, Elizabeth
Inda, Carmen
Koren, John 3rd
Saurat, Nathalie G.
Leist, Marcel http://orcid.org/0000-0002-3778-8693
Gross, Steven S.
Seshan, Venkatraman E.
Klein, Christine
Tomishima, Mark J.
Erdjument-Bromage, Hediye
Neubert, Thomas A. http://orcid.org/0000-0001-7049-2088
Henrickson, Ronald C.
Chiosis, Gabriela
Studer, Lorenz
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA08748, P01 CA186866)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U01 AG032969)
Article History
Received: 24 April 2017
Accepted: 29 August 2018
First Online: 19 October 2018
Competing interests
: Memorial Sloan Kettering Cancer Centre holds the intellectual rights to PU-H71 and uses of labelled HSP90 inhibitors. Samus Therapeutics INC, of which G.C. has partial ownership, has licensed PU-H71 and the chaperome network sensors and their methods of use. The remaining authors declare no competing interests.